Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03, Zacks reports.
Nuvectis Pharma Trading Down 2.5 %
NVCT traded down $0.23 during midday trading on Friday, reaching $8.99. The company's stock had a trading volume of 121,913 shares, compared to its average volume of 126,703. The stock's 50-day moving average is $8.99 and its 200-day moving average is $7.21. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $11.80. The firm has a market capitalization of $212.48 million, a price-to-earnings ratio of -7.75 and a beta of -0.11.
Analysts Set New Price Targets
NVCT has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective (up from $11.00) on shares of Nuvectis Pharma in a research note on Wednesday, April 30th. Laidlaw initiated coverage on Nuvectis Pharma in a report on Monday, March 17th. They set a "buy" rating and a $19.00 price objective on the stock. Finally, Maxim Group initiated coverage on Nuvectis Pharma in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $17.00 target price for the company.
Read Our Latest Analysis on Nuvectis Pharma
Insider Activity at Nuvectis Pharma
In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri bought 12,444 shares of Nuvectis Pharma stock in a transaction on Tuesday, May 6th. The stock was acquired at an average price of $8.59 per share, with a total value of $106,893.96. Following the acquisition, the insider now owns 2,896,565 shares in the company, valued at approximately $24,881,493.35. This trade represents a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 35.78% of the stock is owned by corporate insiders.
About Nuvectis Pharma
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Further Reading
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
